NCT06795022: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 2 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06795022 |
|---|---|
| Title | A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 27, 2025 |
| Completion date | Feb. 25, 2028 |
| Required reporting date | Feb. 24, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 29, 2026 |
| Days late | None |